HJBC/iStock Editorial via Getty Images
- Denali Therapeutics Stock (NASDAQ:DNLI) opened lower on Friday after the company said its partner Sanofi (NASDAQ:SNY) has faced a setback in a mid-stage trial for a co-developed neurology candidate called SAR443820 (DNL788).
- According to the company, Phase 2 The trial called HIMALAYA has not met its primary objective in patients with the rare neurological disease, amyotrophic lateral sclerosis (ALS).
- SAR443820 (DNL788), an oral RIPK1 inhibitor, failed to meet the primary endpoint of change in a clinical measure called the ALS Functional Rating Scale-Revised (ALSFRS-R) in the trial, Sanofi (SNY) said.
- However, the French pharmaceutical company will continue to overtake the candidate in other Phase 2 trial for multiple sclerosis, an immune-mediated neurological condition.
- SAR443820 (DNL788) is in two mid-stage clinical trials for ALS and MS as part of a 2018 collaboration agreement between the two companies.
